Dr. Burt is chief of the Division of Immunotherapy, Department of Medicine, Feinberg School of Medicine, Northwestern University. Dr. Burt pioneered the use of hematopoietic stem cells to treat autoimmune diseases. Dr. Burt performed either America’s first or the world’s first autologous hematopoietic stem cell transplants for numerous immune-mediated diseases, including rheumatoid arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, Crohn’s disease, polymyositis, bullous pemphigus, chronic inflammatory demyelinating polyneuropathy, Behcet’s disease, neurovascular or pulmonary Sjogrens’s syndrome, Wegener’s granulmatosis, Arron’s syndrome (immune-mediated blindness), Devic’s syndrome, and type 1 diabetes. Dr. Burt is the leader of randomized, controlled stem cell trials currently ongoing for: 1) systemic sclerosis: ASSIST (American Scleroderma Stem Cell vs. Immune Suppression Trial), and 2) multiple sclerosis: MIST (Multiple Sclerosis Immune Suppression vs. Stem Cell Transplant). Dr. Burt has also performed the world’s first allogeneic adult stem cell transplants for rheumatoid arthritis, systemic sclerosis, and Crohn’s disease. Dr. Burt was recognized by Scientific American along with Al Gore (former U.S. Vice President) and Steve Jobs (former chief executive officer of Apple Computers) as one of the top 50 people in the world for improving humanity due to his pioneering stem cell work. Dr. Burt’s stem cell trials are being conducted at San Louis Hospital (Paris, France), Uppsala University (Stockholm, Sweden) and the University of Sao Paolo (Ribeirao Preto, Brazil). In 2011, Science Illustrated recognized Dr. Burt’s stem cell work as one of the top 10 advances of the decade. Refer to www.stemcell-immunotherapy.org.
The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research
VATICAN CITY, June 16, 2011 — NeoStem, Inc. (“NeoStem” or the “Company”) (NYSE Amex: NBS), an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units – U.S. adult stem … Continue reading →
Opening ceremony featuring Church officials
Expert presentation on the state of adult stem cell science
Interactive discussions on the scientific, cultural and ethical implications
Breakout sessions to formulate action steps within geographic regions
Unprecedented exposure through Vatican media collaborations